Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.65 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 6/20 | 0.58 |
| ▸ | HTR7 | P34969 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12946412 | 0.88 | PARP1 (0.67) | PARP1PARP2HTR1AHTR7KDM4E | |
| SCHEMBL6796265 | 0.85 | PARP1 (0.70) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL14129602 | 0.83 | KDM4E (0.79) | PARP1PARP2HTR1AHTR7KDM4E | |
| SCHEMBL6795921 | 0.83 | PARP1 (0.70) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL9009947 | 0.82 | KDM4E (0.65) | PARP1PARP2HTR1AHTR7KDM4E | |
| SCHEMBL31060680 | 0.79 | PARP1 (1.00) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL6795915 | 0.76 | PARP1 (0.70) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL14981676 | 0.75 | PARP1 (1.00) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL9070730 | 0.74 | PARP1 (0.65) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL6796582 | 0.74 | GAA (0.76) | PARP1PARP2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885HTR1A 1036/4885 |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885HTR1A 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.